Drug treatments, including conventional chemotherapy, molecular target therapy, as well as updated immunotherapy, play the most important role in the survival of cancer patients. However, resistance to drug treatment is one of the most important factors contributing to the high mortality rate of cancer. Metabolic perturbations are known as hallmarks of cancer, compared to cells in most normal tissues, the unique alterations in cellular metabolic pathways in cancer cells make them resistant to cancer therapy. Moreover, host metabolic factors, such as metabolites derived from carbohydrate, amino acid, lipid, and commensal gut microbiota, have also been recognized as modulators of the cancer microenvironment and targeted for therapeutic gain. Metabolic alterations in cancer cells and host patients include many pathways, and exploring these modified pathways and their signaling will help to understand the regulation of metabolism and cancer therapy. In fact, metabolic factors have recently been recognized as one of the important targets for developing novel combination drugs to overcome resistance to chemotherapy, targeted therapy, and immunotherapy.
This Research Topic on Frontiers in Oncology aims to highlight the ongoing challenges in the field of drug resistance and cancer cell metabolism as well as host metabolism and to develop these findings into preclinical and clinical outcomes.
We welcome submissions of Review, Original Research, Perspective, and Clinical Trial covering, but not limited to, the following sub-topics:
- Novel mechanisms of metabolic pathway and signaling in cancer cells involved in drug resistance
- How host metabolic factors as modulators of cancer microenvironment affect the sensitivity to drug treatment
- How metabolites derived from commensal microbiota regulate the drug resistance in cancer treatment
- Novel targets and strategies for regulating metabolism to overcome drug resistance in cancer treatment
- Clinical proof of concept for novel approaches to overcome drug resistance in cancer treatment
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Drug treatments, including conventional chemotherapy, molecular target therapy, as well as updated immunotherapy, play the most important role in the survival of cancer patients. However, resistance to drug treatment is one of the most important factors contributing to the high mortality rate of cancer. Metabolic perturbations are known as hallmarks of cancer, compared to cells in most normal tissues, the unique alterations in cellular metabolic pathways in cancer cells make them resistant to cancer therapy. Moreover, host metabolic factors, such as metabolites derived from carbohydrate, amino acid, lipid, and commensal gut microbiota, have also been recognized as modulators of the cancer microenvironment and targeted for therapeutic gain. Metabolic alterations in cancer cells and host patients include many pathways, and exploring these modified pathways and their signaling will help to understand the regulation of metabolism and cancer therapy. In fact, metabolic factors have recently been recognized as one of the important targets for developing novel combination drugs to overcome resistance to chemotherapy, targeted therapy, and immunotherapy.
This Research Topic on Frontiers in Oncology aims to highlight the ongoing challenges in the field of drug resistance and cancer cell metabolism as well as host metabolism and to develop these findings into preclinical and clinical outcomes.
We welcome submissions of Review, Original Research, Perspective, and Clinical Trial covering, but not limited to, the following sub-topics:
- Novel mechanisms of metabolic pathway and signaling in cancer cells involved in drug resistance
- How host metabolic factors as modulators of cancer microenvironment affect the sensitivity to drug treatment
- How metabolites derived from commensal microbiota regulate the drug resistance in cancer treatment
- Novel targets and strategies for regulating metabolism to overcome drug resistance in cancer treatment
- Clinical proof of concept for novel approaches to overcome drug resistance in cancer treatment
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
